Articles From: Technician Demand Rises, Universal Technical Institute Funds $1 Million Scholarship Program to CORRECTING and REPLACING Stellus Capital Investment Corporation to Report First Quarter 2013 Financial Results and Hold Conference Call


2013/4/23
New scholarship program to support the immediate demand for technicians in the transportation industry SCOTTSDALE, Ariz.
Sign-up for Technician Demand Rises, Universal Technical Institute Funds $1 Million Scholarship Program investment picks
2013/4/23
An experimental drug cocktail from Bristol-Myers Squibb Co.
Sign-up for Bristol Says Results of Hepatitis C Drug Trial are Positive investment picks
2013/4/23
JERUSALEM --Israeli online translation company Babylon Ltd.
Sign-up for Israeli Internet Translation Co Babylon Signs Agreement With Yahoo investment picks
2013/4/23
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company’s investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus (HCV) infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress 2013) in Amsterdam, The Netherlands.
Sign-up for Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C investment picks
2013/4/23
- Phase 1 Results Further Demonstrate Potency of ACH-3102 in Genotypes 1a and 1b and Against Resistant HCV- AMSTERDAM, The Netherlands, April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of new data demonstrating the efficacy, safety, tolerability, and combinability of ACH-3102, a second-generation, pan-genotypic NS5A inhibitor, at the 48 th Annual Meeting of the European Association for the Study of the Liver (EASL) during the International Liver Congress 2013.
Sign-up for Achillion Presents New Data on ACH-3102 to Treat Hepatitis C at the International Liver Congress investment picks
2013/4/23
http://media.marketwire.com/attachments/201111/35212_gentex.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1009404&ProfileId=051205&sourceType=1 ZEELAND, MI --
Sign-up for Gentex Announces 1st Quarter 2013 Financial Results Conference Call Webcast investment picks
2013/4/23
InterOil Corporation Announces the Retirement of CEO Phil Mulacek Canada NewsWire PORT MORESBY , Papua New Guinea and HOUSTON , April 23, 2013 /CNW/ - InterOil Corporation (NYSE:IOC) (POMSoX:IOC) ("InterOil") today announced the retirement of its founder and Chief Executive Officer, Phil Mulacek, effective April 30, 2013 .
Sign-up for InterOil Corporation Announces the Retirement of CEO Phil Mulacek investment picks
2013/4/23
High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection Canada NewsWire The study results will be presented this week at the International Liver Congress, the 48 th annual meeting of the European Association for the Study of the Liver (EASL), in Amsterdam .
Sign-up for High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection investment picks
2013/4/23
Bristol-Myers Squibb Company (NYSE: BMY) today announced additional, interim Phase II data demonstrating that 12- and 24-week Triple DAA treatment regimens of daclatasvir (DCV), asunaprevir (ASV) and BMS-791325 (’325) achieved high rates of sustained virologic response (SVR) of up to 94%, in treatment-naïve, genotype 1 chronic hepatitis C patients, at time points ranging from 4 to 36 weeks post-treatment depending on the treatment group.
Sign-up for High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection investment picks
2013/4/23
Polaris Industries Inc. (NYSE: PII) today reported record first quarter net income of $75.5 million, or $1.07 per diluted share, for the quarter ended March 31, 2013.
Sign-up for Polaris Reports Record First Quarter 2013 Results; EPS Increased 26% to $1.07 on 11% Sales Growth investment picks
2013/4/23
--First quarter 2013 net revenue was $470.4 million, an increase of 5.6% from the fourth quarter 2012, and a decrease of (4.4)% from the first quarter 2012.
Sign-up for Sensata Technologies Holding N.V. Announces First Quarter 2013 Results investment picks
2013/4/23
NEW KEY LIME TREATS AND A STAYCATION GIVEAWAY FROM KRISPY KREME WINSTON SALEM, N.C. , April 23, 2013 /PRNewswire/ -- Summer sweetness is now in season with two new sun-kissed and handpicked Key Lime treats from Krispy Kreme®. Key Lime Cake and Key Lime Cheesecake Doughnuts are available April 22 through June 23, 2013 at participating Krispy Kreme US and Canadian locations.
Sign-up for Take Your Tastebuds On A Staycation investment picks
2013/4/23
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0868393001&sourceType=1 http://www.ccnmatthews.com/logos/20110215-bayfield.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Bayfield Drills 11.0m of 12.19 g/t Gold and 30.05 g/t Silver in Rainy River, NW Ontario investment picks
2013/4/23
New LCA methodology delivers first EPD process that allows for the production of labels for every product online, in real-time SAN JOSE, Calif.
Sign-up for Central Concrete Announces First Environmental Product Declarations (EPDs) for Concrete Mixes in the United States investment picks
2013/4/23
LAFAYETTE, La.
Sign-up for Home Bancorp Announces 2013 First Quarter Results investment picks
2013/4/23
Athabasca Oil Corporation to Hold 2013 First Quarter Conference Call and Annual General Meeting of Shareholders on April 30, 2013 Canada NewsWire An audio webcast of the conference call will also be available via Athabasca's website, www.atha.com or via the following URL: http://www.newswire.ca/en/webcast/detail/1127495/1229783 .
Sign-up for Athabasca Oil Corporation to Hold 2013 First Quarter Conference Call and Annual General Meeting of Shareholders on April 30, 2013 investment picks
2013/4/23
PORT MORESBY, Papua New Guinea and HOUSTON , April 23, 2013 /PRNewswire/ -- InterOil Corporation (NYSE:IOC) (POMSoX:IOC) ("InterOil") today announced the retirement of its founder and Chief Executive Officer, Phil Mulacek , effective April 30, 2013 .
Sign-up for InterOil Corporation Announces the Retirement of CEO Phil Mulacek investment picks
2013/4/23
SHANGHAI , April 23, 2013 /PRNewswire/ -- JinkoSolar Holding Co., Ltd.
Sign-up for JinkoSolar Completes the Largest Rooftop PV System in a Desalination Plant in Partnership with Soltec Energias Renovables investment picks
2013/4/23
Introducing the one and only Seagram Cider Mix Pack Canada NewsWire KITCHENER, ON, April 23, 2013 /CNW/ - Brick Brewing Co.
Sign-up for Introducing the one and only Seagram Cider Mix Pack investment picks
2013/4/23
- ACH-3102 deemed safe and well-tolerated following 12 weeks of therapy - - High barrier to resistance demonstrated with no on-treatment virologic breakthrough observed - - Novel NS5A inhibitor study supports differentiated profile of ACH-3102 - NEW HAVEN, Conn., April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced updated interim safety and efficacy results, including early sustained virologic response (SVR4) data, from the pilot Phase 2 trial evaluating once-daily ACH-3102 plus ribavirin (RBV) in treatment-naïve patients with genotype 1b, IL28B CC subtype, chronic hepatitis C virus (HCV) infection.
Sign-up for Achillion Announces Updated Phase 2 Results Including Early Sustained Virologic Response on ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patients investment picks
2013/4/23
BEDMINSTER, N.J. and DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Food and Drug Administration (FDA) has accepted its Supplemental New Drug Application (sNDA) seeking approval for the marketing and sale of Vascepa (R) (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides (TG ≥200 mg/dL and <500 mg/dL) with mixed dyslipidemia.
Sign-up for Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia investment picks
2013/4/23
InVivo Therapeutics Holdings Corp.
Sign-up for InVivo Enters Commercialization Phase, Adds John A. McCarthy to Board of Directors investment picks
2013/4/23
Acacia Research Corporation (Nasdaq: ACTG) announced today that its Board of Directors has approved the adoption of a cash dividend policy that calls for the payment of an expected total annual cash dividend of $0.50 per common share, payable in the amount of $0.125 per share per quarter.
Sign-up for Acacia Research Corporation Announces Adoption of Cash Dividend Policy of $0.50 per Share Annual Dividend, Payment of Initial Quarterly Dividend and Extension of $100 Million Share Repurchase Plan investment picks
2013/4/23
Enerplus Announces Cash Dividend for May 2013 Canada NewsWire CALGARY , April 23, 2013 /CNW/ - Enerplus Corporation ("Enerplus") (TSX: ERF) (NYSE: ERF) announces that a cash dividend in the amount of CDN$0.09 per share will be payable on May 21, 2013 to all shareholders of record at the close of business on May 3, 2013 .
Sign-up for Enerplus Announces Cash Dividend for May 2013 investment picks
2013/4/23
Agriculture Segment Achieves Record Operating Earnings, Company Raises Dividend WILMINGTON, Del.
Sign-up for DuPont Reports 1Q 2013 Operating EPS of $1.56 investment picks
2013/4/23
DUBLIN, Calif., April 23, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) , a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that James S.J. Manuso, PhD, chairman and chief executive officer, will present at the Needham 12th Annual Healthcare Conference on Tuesday April 30 th in New York City.
Sign-up for Astex Pharmaceuticals to Present at Needham Healthcare Conference investment picks
2013/4/23
Air Canada Toronto-Dublin Flights to be Extended Year-round in 2014 with Introduction of Air Canada rouge Service Canada NewsWire Emerald Isle becomes fourth European destination in Air Canada rouge network MONTREAL , April 23, 2013 /CNW Telbec/ - Air Canada today announced that its current seasonal service between Toronto and Dublin, Ireland will be converted to year-round service operated by its new leisure carrier, Air Canada rouge, beginning in 2014.
Sign-up for Air Canada Toronto-Dublin Flights to be Extended Year-round in 2014 with Introduction of Air Canada rouge Service investment picks
2013/4/23
Pacific Premier Bancorp, Inc. (NASDAQ: PPBI) ("Pacific Premier"), the holding company of Pacific Premier Bank (the "Bank"), announced today that it has received regulatory approval from the Federal Reserve Bank of San Francisco and the California Department of Financial Institutions for its acquisition of San Diego Trust Bank ("SDTB"), a California-chartered bank located in San Diego, California.
Sign-up for Pacific Premier Bancorp, Inc. Announces Receipt of Regulatory Approval for Acquisition of San Diego Trust Bank investment picks
2013/4/25
Second graph, first sentence of release dated April 23, 2013 should read: Stellus Capital Investment Corporation will host a conference call to discuss these results on Friday, May 10, 2013, at 9:00 a.m. Eastern Daylight Time.
Sign-up for CORRECTING and REPLACING Stellus Capital Investment Corporation to Report First Quarter 2013 Financial Results and Hold Conference Call investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Technician Demand Rises, Universal Technical Institute Funds $1 Million Scholarship Program to CORRECTING and REPLACING Stellus Capital Investment Corporation to Report First Quarter 2013 Financial Results and Hold Conference Call
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity